journal article·2025-05Open access

High‐Valence Selenium Nanotherapeutics Downregulates MUC16 to Drive Precise Ovarian Cancer Therapy through Redox Perturbation

Xiaoli Hu, Zhongwen Yuan, Guanning Huang, Mingkai Chen, Tianfeng Chen, Lizhen He

Advanced Functional Materials· Volume 35· Issue 22

Abstract

Abstract Abnormal expression of transmembrane mucin 16 (MUC16) in ovarian cancer (OC) can promote progression of epithelial–mesenchymal transformation, enhance tumor cell proliferation, migration, and invasion. Therefore, herein a targeted therapeutic high‐valence selenium (Se) nanomedicine (MUC16‐SeMnf@Res) is designed, which can target MUC16 to recognize OC and simultaneously inhibit MUC16 expression to achieve efficient treatment of OC. The valence bidirectional editing strategy is used to design and synthesize a high‐valence Se nanosystem (SeMnf) through triggering a redox reaction between triclinic Se and manganese dioxide nanoflower (Mnf), and inducing the valence conversion to Se4+ and Mn2+. The high‐valence Se4+ and increased Mn2+ ratio within SeMnf disrupt intracellular redox homeostasis by inducing glutathione (GSH) depletion and reactive oxygen species (ROS) overproduction. Moreover, the effects of ROS overproduction are further amplified by loaded resveratrol (Res), which significantly induces mitochondrial dysfunction and inhibited MUC16 expression, then promoting caspase‐activated cell apoptosis as well as migration inhibitory. Taken together, this study not only sheds light on the important role of MUC16 in designing OC‐targeting drugs, but also provides a simple and translational strategy by developing Se nanotherapeutics with strong redox‐homeostasis disrupting capability to realize MUC16‐targeting therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Carbon and Quantum Dots Applications · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Obstetrics and Gynecology The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang 325000 China

College of Chemistry and Materials Science, Department of Oncology of The First Affiliated Hospital Jinan University Guangzhou 510632 China

Funding

National Key Research and Development Program of China · National Science Fund for Distinguished Young Scholars · National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province · China Postdoctoral Science Foundation

References (56)

Show source-provided references
1. 10.3322/caac.2159010.3322/caac.21590 ↗
2. 10.3322/caac.2182010.3322/caac.21820 ↗
3. 10.1021/acsnano.2c0495610.1021/acsnano.2c04956 ↗
4. 10.1001/jamaoncol.2023.019710.1001/jamaoncol.2023.0197 ↗
5. 10.3390/diagnostics1304071310.3390/diagnostics13040713 ↗
6. 10.1016/j.ejso.2019.11.52010.1016/j.ejso.2019.11.520 ↗
7. 10.1097/COC.000000000000102410.1097/COC.0000000000001024 ↗
8. 10.1002/adfm.20240734910.1002/adfm.202407349 ↗
9. 10.1007/s10238-024-01365-510.1007/s10238-024-01365-5 ↗
10. 10.1186/s13048-024-01485-210.1186/s13048-024-01485-2 ↗
11. 10.1016/j.heliyon.2023.e1922110.1016/j.heliyon.2023.e19221 ↗
12. 10.1158/0008-5472.CAN-15-105010.1158/0008-5472.CAN-15-1050 ↗
13. 10.1371/journal.pmed.100329510.1371/journal.pmed.1003295 ↗
14. 10.1016/j.jpba.2024.11608010.1016/j.jpba.2024.116080 ↗
15. 10.3390/cancers1506182310.3390/cancers15061823 ↗
16. 10.3892/ol.2022.1320010.3892/ol.2022.13200 ↗
17. 10.1038/s41467-022-32272-610.1038/s41467-022-32272-6 ↗
18. 10.1155/2021/838825810.1155/2021/8388258 ↗
19. 10.1002/advs.20230863210.1002/advs.202308632 ↗
20. 10.1016/j.ccr.2022.21489710.1016/j.ccr.2022.214897 ↗
21. 10.1002/smll.20231001810.1002/smll.202310018 ↗
22. 10.1016/j.biomaterials.2022.12162010.1016/j.biomaterials.2022.121620 ↗
23. 10.1002/anie.20200365310.1002/anie.202003653 ↗
24. 10.1002/adfm.20220033110.1002/adfm.202200331 ↗
25. 10.1002/adfm.20231015810.1002/adfm.202310158 ↗
26. 10.1002/adfm.20221336410.1002/adfm.202213364 ↗
27. 10.1021/jacs.2c0880210.1021/jacs.2c08802 ↗
28. 10.1039/c3cs60272a10.1039/c3cs60272a ↗
29. 10.1002/adfm.20230205410.1002/adfm.202302054 ↗
30. 10.1021/acs.jmedchem.1c0185910.1021/acs.jmedchem.1c01859 ↗
31. 10.1039/D3TB00064H10.1039/D3TB00064H ↗
32. 10.1002/adfm.20240126410.1002/adfm.202401264 ↗
33. 10.1002/adfm.20221297010.1002/adfm.202212970 ↗
34. 10.1016/j.biomaterials.2021.12135810.1016/j.biomaterials.2021.121358 ↗
35. 10.1021/ja206203c10.1021/ja206203c ↗
36. 10.1016/j.biomaterials.2023.12245210.1016/j.biomaterials.2023.122452 ↗
37. 10.1002/advs.20240203910.1002/advs.202402039 ↗
38. 10.1002/adma.20200854010.1002/adma.202008540 ↗
39. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
40. 10.1002/smtd.20220126610.1002/smtd.202201266 ↗
41. 10.1016/j.jechem.2020.05.05610.1016/j.jechem.2020.05.056 ↗
42. 10.1002/smll.20231011810.1002/smll.202310118 ↗
43. 10.1016/j.biomaterials.2023.12232110.1016/j.biomaterials.2023.122321 ↗
44. 10.3390/molecules2518428210.3390/molecules25184282 ↗
45. 10.1007/s10495-021-01689-710.1007/s10495-021-01689-7 ↗
46. 10.1016/j.canlet.2021.05.00110.1016/j.canlet.2021.05.001 ↗
47. 10.3390/ijms1812258910.3390/ijms18122589 ↗
48. 10.1530/ERC-13-017110.1530/ERC-13-0171 ↗
49. 10.3390/life1308168910.3390/life13081689 ↗
50. 10.3390/ijms23191204110.3390/ijms231912041 ↗
51. 10.3390/cancers1412288510.3390/cancers14122885 ↗
52. 10.1002/advs.20190279510.1002/advs.201902795 ↗
53. 10.1016/j.foodchem.2022.13276610.1016/j.foodchem.2022.132766 ↗
54. 10.3390/nano1010189810.3390/nano10101898 ↗
55. 10.1016/j.omto.2021.05.01310.1016/j.omto.2021.05.013 ↗
56. 10.1039/D1BM00348H10.1039/D1BM00348H ↗